• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Mallinckrodt plc

    7/2/21 8:05:59 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNK alert in real time by email
    DEFA14A 1 d180940ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐   Definitive Proxy Statement
    ☒   Definitive Additional Materials
    ☐   Soliciting Material Pursuant to §240.14a-12

    Mallinckrodt public limited company

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒   No fee required.
    ☐   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
      (1)  

    Title of each class of securities to which transaction applies

     

         

      (2)  

    Aggregate number of securities to which transaction applies

     

         

      (3)  

    Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined)

     

         

      (4)  

    Proposed maximum aggregate value of transaction

     

         

      (5)  

    Total fee paid

     

         

    ☐   Fee paid previously with preliminary materials.
    ☐   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
      (1)  

    Amount Previously Paid

     

         

      (2)  

    Form, Schedule or Registration Statement No.

     

         

      (3)  

    Filing Party

     

         

      (4)  

    Date Filed

     

         

     

     

     


                                      
                            
       

     

    Your Vote Counts!

              

    LOGO

     

     

     

    MALLINCKRODT PLC 

     

    2021 Annual General Meeting

    Vote by August 12, 2021

    11:59 PM ET

                 
       
     

    LOGO     

       

    C/O MALLINCKRODT PLC

    COMPANY SECRETARY

    COLLEGE BUSINESS & TECHNOLOGY PARK

    CRUISERATH, BLANCHARDSTOWN

    DUBLIN 15, IRELAND

            
       

        

        

       
     
     
                  
     
         

         D55979-P59293

                                           
                
               

     You invested in MALLINCKRODT PLC and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual General Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on August 13, 2021.

     Get informed before you vote

    View the Notice and Proxy Statement, including resolutions; Annual Report on Form 10-K, as amended; and Irish Statutory Accounts, including related reports online OR you can receive a free paper or email copy of the material(s) by requesting prior to July 30, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote. com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

     

    LOGO

     

     

    *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

    V1


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the

    upcoming shareholder meeting. Please follow the instructions on

    the reverse side to vote these important matters.

     

      Voting Items    Board
    Recommends
     

    Item 1 - Election of Directors

      
     

    Nominees:

      
     

    1a.

       David R. Carlucci    LOGO  For
     

    1b.

       J. Martin Carroll    LOGO  For
     

    1c.

       Paul R. Carter    LOGO  For
     

    1d.

       David Y. Norton    LOGO  For
     

    1e.

       Carlos V. Paya, M.D.    LOGO  For
     

    1f.

       JoAnn A. Reed    LOGO  For
     

    1g.

       Angus C. Russell    LOGO  For
     

    1h.

       Mark C. Trudeau    LOGO  For
     

    1i.

       Anne C. Whitaker    LOGO  For
     

    1j.

       Kneeland C. Youngblood, M.D.    LOGO  For
     

       Item 2 - Approve, in a non-binding vote, the re-appointment of the independent auditors and authorize, in a binding vote, the Audit Committee to set the auditors’ remuneration.

       LOGO  For
     

       Item 3 - Advisory vote to approve the Company’s executive compensation.

       LOGO  For

        

      

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”.

    D55980-P59293

    Get the next $MNK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNK
    SEC Filings

    View All

    Mallinckrodt plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/5/21 6:01:46 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc filed SEC Form 8-K: Leadership Update

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/3/21 4:31:03 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Mallinckrodt plc

    10-Q - Mallinckrodt plc (0001567892) (Filer)

    11/2/21 6:43:01 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

    Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac

    8/30/23 11:54:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

    Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th

    8/28/23 12:17:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

    Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur

    8/23/23 8:22:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Norton David Y sold $1,334 worth of Ordinary Shares (5,080 units at $0.26), closing all direct ownership in the company

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:09:30 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: O'Neill Hugh M. sold $537 worth of Ordinary Shares (2,100 units at $0.26), decreasing direct ownership by 3% to 76,856 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:10:08 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: A Kathy Schaefer disposed of $256 worth of Ordinary Shares (675 units at $0.38), decreasing direct ownership by 3% to 22,934 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    4/5/21 4:24:38 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Leadership Updates

    Live Leadership Updates

    View All

    Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

    DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece

    1/12/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/12/21 2:55:13 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/5/21 2:58:50 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    10/22/21 4:48:46 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Financials

    Live finance-specific insights

    View All

    Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

    Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli

    5/9/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt to Report Earnings Results for First Quarter 2023

    DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website

    4/24/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance

    Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022. 

    2/28/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care